Therapeutic advances in rheumatology with the use of recombinant proteins

Nature Clinical Practice Rheumatology

Volumn 4, Issue 11, 2008, Pages 605-614

  Rothe, Achim ^a   Power, Barbara E ^b   Hudson, Peter J ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Recombinant Technologies at Patrys Ltd   (Australia)

^c AntibOZ Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIMETHYLAMINOAZOBENZENE; ABATACEPT; ADALIMUMAB; AFLIBERCEPT; AMG 714; ANTIRHEUMATIC AGENT; ART 621; ATACICEPT; ATLIZUMAB; BELIMUMAB; BEVACIZUMAB; CD20 ANTIBODY; CELL SURFACE RECEPTOR; CERTOLIZUMAB PEGOL; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INFLIXIMAB; OSTEOPROTEGERIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; RITUXIMAB; TGN 1412; TOSITUMOMAB; TRU 015; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY LIBRARY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BINDING AFFINITY; BIOLOGICAL THERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE DEPLETION; MOLECULAR EVOLUTION; MULTIPLE ORGAN FAILURE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN ENGINEERING; PSORIATIC ARTHRITIS; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; RHEUMATOLOGY;

ANIMALS; ANTIBODIES; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 59149104627     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0909     Document Type: Review

References (55)

1. Olafsen T et al. (2006) Tunable pharmacokinetics: Modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 1: 2048-2060
2. Walsh G and Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24: 1241-1252
3. Holliger P and Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136
4. Lipovsek D et al. (2007) Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: Molecular convergence with singledomain camelid and shark antibodies. J Mol Biol 368: 1024-1041
5. Cohen SB et al. (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63: 1062-1068
6. Hosse RJ et al. (2006) A new generation of protein display scaffolds for molecular recognition. Protein Sci 15: 14-27
7. Moreland LW et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141-147
8. Wang H et al. (2001) TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2: 632-637
9. Mosquera LA et al. (2005) In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J Immunol 174: 4381-4388
10. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23: 1117-1125
11. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23: 1105-1116
12. Rothe A et al. (2006) In vitro display technologies reveal novel biopharmaceutics. FASEB J 20: 1599-1610
13. Lipovsek D and Pluckthun A (2004) In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 290: 51-67
14. Marks JD (2004) Antibody affinity maturation by chain shuffling. Methods Mol Biol 248: 327-343
15. Valjakka J et al. (2002) Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains. J Biol Chem 277: 44021-44027
16. Baker KP et al. (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48 3253-3265
17. Bayry J et al. (2007) Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: Rationale and mechanisms of action. Nat Clin Pract Rheumatol 3: 262-272
18. Chambers RS (2005) High-throughput antibody production. Curr Opin Chem Biol 9: 46-50
19. Kenanova V et al. (2007) Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 67: 718-726
20. Ward ES et al. (2005) From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell 16: 2028-2038
21. Woof JM and Burton DR (2004) Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4: 89-99
22. Cartron G et al. (2007) Pharmacokinetics of rituximab and its clinical use: Thought for the best use? Crit Rev Oncol Hematol 62: 43-52
23. Brocchini S et al. (2006) PEGylation of native disulfide bonds in proteins. Nat Protoc 1: 2241-2252
24. Choy EH et al. (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41: 1133-1137
25. Rao BM et al. (2005) Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat Biotechnol 23: 191-194
26. Adams GP et al. (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750-4755
27. Traggiai E et al. (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304: 104-107
28. De Groot AS and Moise L (2007) Prediction of immunogenicity for therapeutic proteins: State of the art. Curr Opin Drug Discov Devel 10: 332-340
29. Silverman GJ and Boyle DL (2008) Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: The B-cell roadblock hypothesis. Immunol Rev 223: 175-185
30. Taylor RP and Lindorfer MA (2007) Drug Insight: The mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 3: 86-95
31. Beers SA et al. (2008) Type II (tositumomab) anti-CD20 monoclonal antibody out performs Type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood [doi:10.1182/ blood-2008-04-149161]
32. Schett G et al. (2005) Mechanisms of Disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1 47-54
33. Miller PD et al. (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 43: 222-229
34. Tarner IH et al. (2007) Emerging targets of biologic therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 3: 336-345
35. Kunisch E et al. (2007) Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: Failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis 66: 1043-1051
36. Strand V et al. (2007) Biologic therapies in rheumatology: Lessons learned, future directions. Nat Rev Drug Discov 6: 75-92
37. van Vollenhoven R et al. (2003) Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: Data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 62: 1195-1198
38. Cobo-Ibanez T and Martin-Mola E (2007) Etanercept: Long-term clinical experience in rheumatoid arthritis and other arthritis. Expert Opin Pharmacother 8: 1373-1397
39. Sandborn WJ et al. (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-238
40. Arana announces start of Phase II trial for lead compound. [http://www.arana.com/text/news_media/2008_html/ press_release_170308.html] (accessed 14 August 2008)
41. Holt LJ et al. (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 21: 283-288
42. Seyler TM et al. (2005) BLyS and APRIL in rheumatoid arthritis. J Clin Invest 115: 3083-3092
43. Ding C and Jones G (2006) Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 7: 464-472
44. Human genome sciences reports positive long-term data for LymphoStat-B in patients with active systemic lupus erythematosus. [http://www.hgsi.com/latest/]
45. Lin WY et al. (2007) Anti-BR3 antibodies: A new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 110: 3959-3967
46. Nishimoto N et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 1162-1167
47. Ferrari-Lacraz S et al. (2004) Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 173: 5818-5826
48. Baslund B et al. (2005) Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum 52: 2686-2692
49. Bruce SP and Boyce EG (2007) Update on abatacept: A selective costimulation modulator for rheumatoid arthritis. Ann Pharmacother 41: 1153-1162
50. Suntharalingam G et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 1018-1028
51. Lainer-Carr D and Brahn E (2007) Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 3: 434-442
52. Strunk J et al. (2006) Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: A pilot study. Rheumatol Int 26: 252-256
53. Holash J et al. (2002) VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398
54. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
55. Parker MH et al. (2005) Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel 18: 435-444